title: Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma.
abstract: BACKGROUND
  Circulating plasma Epstein Barr Virus DNA (EBV-DNA) is a sensitive and specific marker of nasopharyngeal carcinoma (NPC). The mainstay of treatment of metastatic NPC is systemic chemotherapy and resection for solitary metastasis. Despite high response rate to chemotherapy, complete remission is uncommonly seen.
  
  
  METHODS
  We report a case of recurrent metastatic NPC in a 43-year-old man, who achieved complete remission three times with chemotherapy and surgery. Serial plasma EBV-DNA levels were measured during the course of disease. The patient had three episodes of recurrences of NPC manifested as distant metastasis. Both time, rise in the plasma EBV-DNA level preceded detection of recurrences by imaging. Following systemic chemotherapy, he achieved complete remission each time, of which was confirmed by 18-flourodeoxyglucose positron emission tomography and hepatectomy pathology. The plasma EBV-DNA level dropped to zero copy/ml at the time of each remission.
  
  
  CONCLUSIONS
  This case highlights the high chemosensitivity of NPC by illustrating a rare occurrence of complete response of metastatic NPC to chemotherapy. This case also underscores the usefulness of EBV-DNA as a useful tool in monitoring NPC by its ability to detect early recurrence and excellent correlation with treatment response.
authors.affiliation: Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, Hong Kong SAR, China. l_chan@clo.cuhk.edu.hk
authors.forename: Stephen L
authors.initials: SL
authors.lastname: Chan
authors.forename: Edwin P
authors.initials: EP
authors.lastname: Hui
authors.forename: Sing F
authors.initials: SF
authors.lastname: Leung
authors.forename: Anthony T C
authors.initials: AT
authors.lastname: Chan
authors.forename: Brigette B Y
authors.initials: BB
authors.lastname: Ma
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D004279:DNA, Viral / Q000097:blood*; D019788:Fluorodeoxyglucose F18; D004854:Herpesvirus 4, Human / Q000235:genetics*; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000556:secondary / Q000821:virology; D008297:Male; D009303:Nasopharyngeal Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000821:virology; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000556:secondary / Q000821:virology; D049268:Positron-Emission Tomography; D011859:Radiography; D019275:Radiopharmaceuticals; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004279:DNA, Viral; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18